Antibody response against the Epstein-Barr virus-coded nuclear antigen2 (EBNA2) in nasopharyngeal carcinoma.

@article{Chatani1991AntibodyRA,
  title={Antibody response against the Epstein-Barr virus-coded nuclear antigen2 (EBNA2) in nasopharyngeal carcinoma.},
  author={Masashi Chatani and Takanori Teshima and Tokiko Inoue and K Yoshino and Nobuko Ikegami and Katsuya Hirai and Misuzu Shimakage},
  journal={The Laryngoscope},
  year={1991},
  volume={101 6 Pt 1},
  pages={
          626-9
        }
}
  • Masashi Chatani, Takanori Teshima, +4 authors Misuzu Shimakage
  • Published in The Laryngoscope 1991
  • Medicine
  • Specific antibody responses against the Epstein-Barr virus-coded nuclear antigen2 (EBNA2) were evaluated. Thirty-five sera from pretreatment patients of nasopharyngeal carcinoma (NPC) and 12 from healthy adults were tested. Although the anti-EBNA2 response did not show any correlation with T stage, overall stage, or histopathology, it showed a correlation with the N stage of the disease. In a serological follow-up study, 17 (85%) of 20 patients showed a correlation on the change of antibody… CONTINUE READING

    Create an AI-powered research feed to stay up to date with new papers like this posted to ArXiv

    Citations

    Publications citing this paper.